Radiopharm Theranostics Limited a clinical-stage radiotherapeutics company, engages in the research and development of radiopharmaceutical products for diagnostic and therapeutic uses in areas with high unmet medical needs. The company develops several products, including RAD101, a pivalate brain metastasis diagnostic; RAD102, a pivalate therapeutic; RAD201a, a Nano-mAb HER-2 breast diagnostic; RAD202, a Nano-mAb HER-2 breast therapeutic; RAD203, a Nano-mAb PDL1 non-small cell lung diagnostic; and RAD204, a Nano-mAb PDL1 non-small cell lung therapeutic. Additionally, it is developing RAD301 and RAD302, which are Avß6-Integrin pancreatic diagnostic and therapeutic products; RAD401, a PSA-mAb prostate cancer diagnostic; RAD402, a PSA-mAb prostate cancer therapeutic; RAD601, a PTPµ glioblastoma diagnostic; and RAD602, a PTPµ glioblastoma therapeutic. The company has a strategic agreement with Lantheus Holdings, Inc. to advance the clinical development of radiopharmaceuticals. The company was incorporated in 2021 and is based in Carlton, Australia.
Price analytics
Returns
1 day
16.7%
1 week
-12.5%
1 month
-30.0%
3 months
-65.0%
6 months
-66.7%
1 year
-78.8%
3 years
-94.3%
Risk
Volatility (1y ann.)
112.5%
Beta vs ASX 200
-0.33
Sharpe (1y)
-0.89
VaR 95% (1-day)
-10.0%
Max drawdown (1y)
-83.8%
Off 1-year high
-81.1%
Technicals
RSI(14)
40
vs 50DMA
-30.8%
vs 200DMA
-62.0%
Trend
Death cross
Fundamental trends
Financial statements
Loading…
Scoring breakdown
(2 Oct 2026)
Value96.5
Trailing P/E
—
Forward P/E
100
PEG ratio
—
EV / EBITDA
100
Price / Book
97
Price / Sales
84
Growth100.0
Revenue growth (1y)
100
Revenue CAGR (3y)
100
EPS growth (1y)
—
EPS CAGR (3y)
—
Financial Health10.6
Net debt / EBITDA
—
Interest coverage (EBIT/interest)
0
Current ratio
21
Debt / Equity
—
Quality (Profitability & Cash Flow)0.0
Return on equity
0
Return on assets
0
Operating margin
0
Net margin
0
Cash conversion (OCF / net income)
—
Dividend / Income—
No meaningful dividend — pillar excluded from the overall score.
Momentum0.6
6-month return vs ASX 200
0
Price vs 200-day average
0
Price vs 50-day average
0
Position in 52-week range
3
Hover a row's info icon for the exact rule. Bounds and weights are configurable in
the Django admin (Scoring configuration).